Wegovy — branded semaglutide for chronic weight management.

Wegovy is semaglutide formulated and branded by Novo Nordisk for chronic weight management. FDA-approved in 2021 for adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (T2DM, hypertension, dyslipidemia, sleep apnea).

Same active molecule as Ozempic (also semaglutide, but FDA- approved for T2DM instead of weight management). With the FDA shortage of semaglutide resolved, compounded versions are restricted to narrow, physician-documented clinical-need cases — for most patients the real decision is Wegovy vs Ozempic vs Zepbound, driven by indication and insurance coverage.

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide 1, which slows gastric emptying, increases insulin secretion in response to glucose, suppresses glucagon, and acts centrally on satiety pathways in the hypothalamus.

The combined effect: patients eat less, feel full sooner, have steadier blood glucose, and lose weight progressively over 12–18 months. The SELECT trial (n=17,604) showed 20% reduction in major adverse cardiovascular events independent of weight loss, so the cardiovascular benefits are real and measurable.

Wegovy tends to fit:

• Adults with BMI ≥30, or ≥27 with comorbidity (FDA criteria)
• Patients with insurance plans that actually cover Wegovy (still uncommon)
• Patients who want branded supply over compounded for risk-tolerance reasons
• Patients building a 12–24 month metabolic protocol, not a short-term intervention

Wegovy uses a fixed five-step dose escalation: 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg, once weekly subcutaneous, increasing every 4 weeks. The escalation reduces nausea — going faster increases dropout rates significantly.

Maintenance dose is 2.4mg/week. Some patients respond fully at 1.7mg and don't need to escalate further. We individualize based on response and tolerance.

Mean weight loss at 68 weeks in STEP-1 trial: 14.9%. Real-world results vary; 10–18% is the common range. Cardiovascular benefit from SELECT trial: 20% reduction in MACE. Side effects: nausea, constipation, occasional vomiting during dose escalation. Mostly tolerable with slow titration and dietary adjustments.

We prescribe branded, FDA-approved Wegovy — and we'll help you pursue insurance coverage, which is where the real savings live. Compounded semaglutide is not a menu item: with the shortage resolved, it's permitted only where your physician documents a specific clinical need the approved product can't meet, and that determination happens at your consult, not at checkout. Whatever the path, it's the same physician relationship, lab cadence, and side-effect management — no upsells either direction.